Haishan Wang was born in Weifang, Shandong, China, in 1965. He graduated from the School of Pharmaceutical Sciences, Beijing Medical University (Peking University Health Science Center) in 1986, obtaining the B.S. degree, and Peking Union Medicinal College and Chinese Academy of Medical Sciences (CAMS) in 1991, obtaining the Ph.D. degree. He worked on design, synthesis, and development of novel quinolone and beta-lactam antibiotics at the Institute of Medicinal Biotechnology, CAMS, as a Research Assistant (1991), as a Research Associate (1992–1994), and as an Associate Investigator/Professor (1994-1995). He spent one year working on asymmetric synthesis at Institut de Chimie des Substances Naturelles, CNRS, Gif-sur-Yvette, France. He then moved to Singapore and worked on medicinal, combinatorial, and natural product chemistry projects at the Institute of Molecular and Cell Biology, National University of Singapore (NUS)/Agency for Science, Technology and Research (A*STAR), as a Research Fellow (1996–2000) and as a Research Associate (2000-2001). In 2001, he joined S*BIO Pte Ltd as a Group Leader in medicinal chemistry. As a Project Leader, he together with the histone deacetylase (HDAC) project team delivered the development candidate SB939, which has an excellent preclinical profile and is now in phase II clinical trials. Besides HDAC inhibitors, he has also been working on inhibitors of kinases (e.g., CDK2, PLK, Aurora, PDK, JAK2, and PI3K/mTOR) and other cancer-relevant targets. He has authored about 25 peer-reviewed research papers published in international journals and eight patents/patent applications. In December 2011, he joined the Institute of Molecular and Cell Biology (IMCB), A*Star, Singapore, as Group Leader of Drug Development Unit, and worked on research and development of anticancer and anti-infective drugs.
Biography Updated on 20 March 2012